Renal Guard CEO Jim Dillon Discusses Spin Out of High Profile Reprieve Cardiovascular

Jim Dillon, president and CEO of Renal Guard, talks about the company’s decision to create Reprieve Cardiovascular, a start-up focusing on heart failure. Reprieve raised $7 million from outside investors, including Abiomed, and counts Serial Entrepreneur Howard Levin as chief medical officer.